| References: |
GW 627368X is a selective and potent competitive antagonist of the EP4 receptor with additional human TP receptor affinity. In competition radioligand bioassays, GW 627368X had affinity for human EP4 and TP receptors with Ki values of 100 nM and 158 nM, respectively. Affinity for all other human prostanoid receptors is >5.0 μM. In human washed platelets, GW 627368X produced 100% inhibition of U-46619 (EC100)-induced aggregation at a concentration of 10 μM. The effects of prostaglandin E2 (PGE2) are transduced by at least four different receptors designated EP1, EP2, EP3, and EP4. For the detailed information of GW-627368X, the solubility of GW-627368X in water, the solubility of GW-627368X in DMSO, the solubility of GW-627368X in PBS buffer, the animal experiment (test) of GW-627368X, the cell expriment (test) of GW-627368X, the in vivo, in vitro and clinical trial test of GW-627368X, the EC50, IC50,and affinity,of GW-627368X, For the detailed information of GW-627368X, the solubility of GW-627368X in water, the solubility of GW-627368X in DMSO, the solubility of GW-627368X in PBS buffer, the animal experiment (test) of GW-627368X, the cell expriment (test) of GW-627368X, the in vivo, in vitro and clinical trial test of GW-627368X, the EC50, IC50,and affinity,of GW-627368X, Please contact DC Chemicals. |
